Scientech Research LLC Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Scientech Research LLC reduced its holdings in Regeneron Pharmaceuticals by 47.3%, owning 1,908 shares valued at $1,210,000 after selling 1,714 shares in the first quarter.
• Analysts have given mixed ratings on REGN shares, with a consensus rating of Moderate Buy and a target price of $817.67, following various upgrades and downgrades from different firms.
• Regeneron reported a strong quarterly earnings result with $12.89 EPS, surpassing expectations and showing a year-over-year revenue increase of 3.6%, reflecting robust performance in the biopharmaceutical sector.

Scientech Research LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 47.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,908 shares of the biopharmaceutical company's stock after selling 1,714 shares during the quarter. Scientech Research LLC's holdings in Regeneron Pharmaceuticals were worth $1,210,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of REGN. Marietta Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after buying an additional 955 shares in the last quarter. Sepio Capital LP raised its position in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after acquiring an additional 842 shares during the period. Finally, KBC Group NV raised its position in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after acquiring an additional 12,793 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $4.13 during midday trading on Friday, hitting $564.07. The company had a trading volume of 223,307 shares, compared to its average volume of 1,094,585. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,170.58. The stock has a market cap of $59.78 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business's 50-day simple moving average is $564.31 and its 200-day simple moving average is $580.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the firm earned $11.56 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective on the stock. Sanford C. Bernstein increased their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Morgan Stanley reissued an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.